UroGen Pharma Ltd.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $109.8M | $90.4M | $82.7M | $64.4M | $48.0M | $11.8M | $18.0K |
| Cost of Revenue | — | $12.4M | $8.9M | $9.4M | $7.7M | $5.2M | $1.0M | — |
| Gross Profit | — | $97.3M | $81.5M | $73.4M | $56.7M | $42.9M | $10.8M | $18.0K |
| Gross Margin | — | 88.7% | 90.2% | 88.7% | 88.1% | 89.3% | 91.4% | 100.0% |
| Operating Expenses | ||||||||
| Research & Development | — | $67.1M | $57.1M | $45.6M | $52.9M | $47.6M | $47.3M | $49.3M |
| SG&A Expense | — | $155.1M | $121.2M | $93.3M | $82.8M | $87.5M | $90.2M | $60.2M |
| Operating Income | — | $-124.9M | $-96.8M | $-65.5M | $-79.0M | $-92.3M | $-126.7M | $-109.5M |
| Operating Margin | — | -113.7% | -107.1% | -79.2% | -122.8% | -192.1% | -1,074.2% | -608,211.1% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-153.4M | $-124.0M | $-98.3M | $-108.0M | $-109.4M | $-125.1M | $-105.1M |
| Income Tax Expense | — | $78.0K | $2.8M | $3.9M | $1.8M | $1.4M | $3.4M | — |
| Net Income | — | $-153.5M | $-126.9M | $-102.2M | $-109.8M | $-110.8M | $-128.5M | $-105.1M |
| Net Margin | — | -139.8% | -140.4% | -123.6% | -170.6% | -230.7% | -1,088.9% | -584,144.4% |
| EPS (Basic) | — | $-3.19 | $-2.96 | $-3.55 | $-4.81 | $-4.96 | $-5.90 | $-5.12 |
| EPS (Diluted) | — | — | — | — | — | $-4.96 | $-5.90 | $-5.12 |
| Shares Outstanding (Basic) | 48.7M | 48.1M | 42.9M | 28.8M | 22.8M | 22.3M | 22.2M | 21.0M |
| Shares Outstanding (Diluted) | 48.7M | 48.1M | 42.9M | 28.8M | 22.8M | 22.3M | 22.2M | 21.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |